Cellectis therapeutics

Launched in 2008 under the name Cellectis Genome surgery, Cellectis therapeutics is dedicated to the development of innovative therapeutic approaches using Meganucleases to treat genetic diseases, cancers and persistent viral infections. Cellectis therapeutics seeks to treat patients suffering from serious diseases resistant to conventional treatment.

Its prospective therapy targets the very DNA sequence responsible for the disease. This DNA sequence may be of congenital origin (in the case of genetic disease) or acquired (in the case of a viral infection or a cancer). The mission of this subsidiary is to fulfill unmet medical needs, giving patients new hope. The therapeutics approach aims to attack the cause of a disease and cure the patient, rather than merely treat its symptoms.

In 2009, Cellectis therapeutics took important steps forward, establishing preliminary data supporting a proof of concept for the antiviral power of Meganucleases against HIV, hepatitis B or herpes viruses, for example. Since its establishment in June 2008, Cellectis therapeutics has worked together with its partners – academic research groups and clinicians all over the world – to transform its research into an effective medical treatment.

In 2010, Cellectis acquired the assets, including the intellectual property, of Cyto Pulse Sciences Inc., a US-based company specialized in the development, manufacturing and commercialization of electroporation technology and equipment. Cellectis therapeutics now continues the development of ex vivo and in vitro electroporation systems for use in the therapeutic field. (learn more about electroporation technology)